Revlimid® shows promising outcomes for non-Hodgkin lymphomas in phase I and II studies
Results of three phase I/II studies evaluating the use of Revlimid® (lenalidomide) – with either standard R-CHOP chemotherapy (R2CHOP) or rituximab – in patients suffering from different types of non-Hodgkin lymphoma have shown promising outcomes.
In the study involving untreated diffuse large B-cell (DLBCL) or grade 3 follicular lymphoma patients, a 100 percent overall response rate (ORR) and 83 percent complete response rate (CRR) were reported. Commenting on this finding, A/Prof Chng Wee Joo, consultant haematologist from the National University Cancer Institute of Singapore, said the findings are encouraging given the fact that DLBCL is an aggressive and one of the most common types of lymphomas.
In a separate phase II study, a 90 percent ORR and 66 percent CRR in patients receiving Revlimid® with rituximab for indolent B-cell non-Hodgkin’s lymphomas were reported. Additionally, patients with follicular lymphoma achieved an 87 percent complete remission rate.
In another phase I/II study, the combination of Revlimid® with rituximab in relapsed/refractory mantle cell lymphoma (MCL) was associated with 57.8 percent ORR and 33 percent CRR, as well as a median overall survival of 25 months.
According to Dr Daryl Tan, consultant from the Department of Haematology in Singapore General Hospital, “The study demonstrates the possibility of effectively treating indolent B-cell lymphomas with novel targeted agents while deferring the upfront use of conventional cytotoxic chemotherapeutic agents.”
“Similarly, the study on mantle cell lymphoma shows that we could further optimise the full potential of rituximab with the addition of lenalidomide. If confirmed by randomised controlled studies, such advances may eventually pave the way towards meeting unmet medical needs in the future,” said Dr Tan.